Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Image

[Articles] Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial

Journal content Created on 12 Nov 2026 The Lancet

Published in

The Lancet, The Lancet (Reed Elsevier)

Content

There is no additional content. Please click on the source link to view more information.

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 68
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement